Have Pharma gone Webinar crazy!?
Article written by Peter Mas-Mollinedo With the outbreak of the Pandemic and the lingering worries of COVID-19 pharmaceutical sales and marketing has taken a hit. There are no… read more.
Article written by Peter Mas-Mollinedo With the outbreak of the Pandemic and the lingering worries of COVID-19 pharmaceutical sales and marketing has taken a hit. There are no… read more.
One in four older Americans had a virtual medical visit in the first three months of the COVID-19 pandemic, most of them by video, a new telehealth poll finds.
The European Medicines Agency’s (EMA) human medicines committee (CHMP) has recommended eight medicines for approval at its June 2020 meeting.
Global regulators have held a workshop designed to nail down the data they will require of companies developing vaccines against COVID-19.
The European Medicines Agency will welcome a new Executive Director by the end of 2020. The change comes as the EU drug watchdog’s current chief, Guido Rasi, is… read more.
The majority of patients with follicular lymphoma (FL) have excellent results when treated with chemotherapy so — even with evolving understanding of disease biology and availability of a parade… read more.
Professor Stephen Ansell (Rochester, USA) discusses the DIAL study
Dr Graham Collins (Oxford, UK) discusses real-world data from patients treated with CD19 CAR-T in England. He then reviews data presented on the risk of fracture following front-line R-CHOP… read more.
Dr Steven Horwitz (New York, USA) discusses new directions for treating PTCL. Written by Thomas R. Collins.
Using rituximab in combination with chemotherapy — tailored based on risk profile and response speed — produced good results in children, adolescents and young adults with classic Hodgkin lymphoma,… read more.
Dr Alison J. Moskowitz (New York, USA) and Dr Graham Collins (Oxford, UK) review the long-term follow up data from brentuximabvedotin and nivolumab for R/R Hodgkin lymphoma Written by Thomas R. Collins
Dr Alison J. Moskowitz (New York, USA) highlights the long-term follow up data for single-agent brentuximab vedotin as pre-transplant salvage.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.